leadf
logo-loader
viewChimeric Therapeutics Ltd
(
ASX:CHM
)

Chimeric Therapeutics appoints experts to Cellular Immunotherapy Scientific Advisory Board

The three appointments “bring deep translational expertise in cellular therapy development and are each very respected visionaries and contributors to the field,” says CEO & MD.

Chimeric Therapeutics Ltd - Chimeric Therapeutics appoints experts to Cellular Immunotherapy Scientific Advisory Board

Chimeric Therapeutics Ltd (ASX:CHM) has appointed three highly regarded cell therapy experts to the company’s Cellular Immunotherapy Scientific Advisory Board.

This Scientific Advisory Board has been established to provide expert guidance on the development of Chimeric’s growing pipeline of cellular immunotherapies.

The appointments are Dr Eric Smith from Dana-Farber Cancer Institute, Dr David G Maloney from Fred Hutchinson Cancer Research Center and University of Chicago’s Dr Michael R Bishop.

Chimeric Therapeutics is undertaking a phase one clinical trial for its CHM 1101 asset, a novel CAR-T therapy for the treatment of patients with Glioblastoma.

“Deep translational expertise”

Chimeric’s CEO and managing director Jennifer Chow said: “We are honoured to have these outstanding individuals joining our Scientific Advisory Board.

“They bring deep translational expertise in cellular therapy development and are each very respected visionaries and contributors to the field.

“As we move into our next phase of growth, we expect the insights and guidance they will bring to the table to be of great value to Chimeric.”

Dr Smith’s experience

Dr Eric Smith is a highly respected translational researcher who specialises in the discovery and development of cellular immunotherapies with a focus on blood cancers.

He is director of translational research, immune effector cell therapies and the head of the Eric Smith Lab for synthetic biology and cellular engineering at the Dana-Farber Cancer Institute and is also a member of the Faculty of Medicine at Harvard Medical School in Boston, Massachusetts.

Dr Smith utilises the latest advances in gene engineering and cellular manipulation to design and screen novel cellular therapy strategies which he then works in collaboration to rapidly advance to the clinic.

He has earned his MD and PhD from the Mount Sinai School of Medicine and later moved to Memorial Sloan Kettering Cancer Center (MSKCC) for his medical oncology fellowship and further research training.

His pre-clinical work has resulted in nine awarded or pending patents, multiple products stemming from his lab work have been translated to the clinic and he is an author of many seminal publications in the field.

Dr Maloney’s experience

David Maloney is a renowned clinician-scientist who has been at the forefront of cellular therapy research and development.

Dr Maloney has been a clinical investigator in more than 15 cellular therapy clinical trials ranging from phase 1, first in human trials through to commercially approved CAR T cell therapies.

He has amassed more than 265 publications in peer-reviewed journals and has received the presidential award from the International Society for Biology Therapy of Cancer.

Maloney received his MD and PhD in cancer biology from Stanford University and completed a fellowship in oncology at Stanford.

In 1994, he joined the faculties of Fred Hutchinson Cancer Research Center and the University of Washington, where he is a member in the Clinical Research Division and a Professor of Medicine in the Division of Oncology.

Dr Bishop’s experience

Dr Michael Bishop is a pioneer and widely recognised expert in cellular therapy research and patient care, with a focus on leukemia and lymphomas.

He has served as an investigator for multiple clinical trials investigating novel cellular immunotherapies, including phase 1 clinical trials for autologous and allogeneic CAR T and TCR products.

An active contributor to medical literature, Dr Bishop has authored more than 200 peer-reviewed articles along with more than 35 book chapters and two books on cancer treatment and research.

He also serves on the editorial board of numerous scientific journals, including Biology of Blood and Marrow Transplantation.

Dr Bishop previously served as the director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago and as a senior investigator and the clinical head of stem cell transplantation for the National Cancer Institute at the National Institutes of Health.

Quick facts: Chimeric Therapeutics Ltd

Follow
ASX:CHM

Price: 0.325 AUD

Market Cap: $108.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Chimeric Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Chimeric Therapeutics Ltd (ASX:CHM)'s Jennifer Chow speaks to Proactive's Andrew Scott from the ASX Small and Mid Cap Conference - September 2021. Chimeric is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Its lead...

5 days, 15 hours ago

3 min read